PharmaCyte Biotech, Inc. - 21 Nov 2023 Form 3 Insider Report for FEMASYS INC (FEMY)

Role
10%+ Owner
Signature
/s/ Joshua N. Silverman, Interim President and CEO
Issuer symbol
FEMY
Transactions as of
21 Nov 2023
Net transactions value
$0
Form type
3
Filing time
28 Nov 2023, 17:06:22 UTC
Next filing
30 May 2024
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding FEMY 6.0% Senior Convertible Note due 2025 21 Nov 2023 Common stock, par value $0.001 per share 4,237,288 $1.18 Direct
holding FEMY Series A Warrants 21 Nov 2023 Common stock, par value $0.001 per share 4,237,288 $1.18 Direct
holding FEMY Series B Warrants 21 Nov 2023 Common stock, par value $0.001 per share 4,237,288 $1.48 Direct
* An asterisk sign (*) next to the price indicates that the price is likely invalid.